X

J&J, AstraZeneca Vaccines Made With Same Technology

Both are now the subject of investigations of clotting in rare instances
By Newser Editors and Wire Services
Posted Apr 13, 2021 11:23 AM CDT

(Newser) – Johnson & Johnson said Tuesday it is delaying the rollout of its coronavirus vaccine in Europe amid a US probe into reports of rare blood clots in some recipients. The announcement came after regulators in the United States said they were recommending a “pause” in administration of the single-dose shot to investigate reports of potentially dangerous blood clots. “We have been reviewing these cases with European health authorities,” Johnson & Johnson said. “We have made the decision to proactively delay the rollout of our vaccine in Europe.” The delay is a further blow to vaccination drives in the European Union, which have been plagued by supply shortages, logistical problems, and concerns over unusual blood clots in a small number of people who received the AstraZeneca vaccine.

story continues below

The blood clot reports prompted several countries in the 27-nation bloc to limit the AstraZeneca vaccine to older age groups, which are more at risk from serious illness when infected with COVID-19. The Johnson & Johnson and AstraZeneca vaccines are made with the same technology. Many leading COVID-19 vaccines train the body to recognize the spike protein that coats the outer surface of the coronavirus. But the J&J and AstraZeneca vaccines use a cold virus, called an adenovirus, to carry the spike gene into the body. Johnson & Johnson uses a human adenovirus to create its vaccine, while AstraZeneca uses a chimpanzee version. The EU ordered 200 million doses of the Johnson & Johnson in 2021. Britain ordered 30 million doses of the J& J vaccine, though UK regulators have not yet approved its use.

(Read more Johnson & Johnson stories.)

We use cookies. By Clicking "OK" or any content on this site, you agree to allow cookies to be placed. Read more in our privacy policy.
Get the news faster.
Tap to install our app.
X